Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

(2013) D. Cohen   BMJ-British Medical Journal

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience

(2011) J. H. Martin et al.   INTERNAL MEDICINE JOURNAL

Molecular mechanisms underlying nutrient-stimulated incretin secretion

(2010) Helen E. Parker et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Exenatide and Rare Adverse Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE